To read the full story, subscribe or sign in.

CSPC NBP gains China rights to Harbour’s batoclimab for ¥150M up front

Oct. 11, 2022

CSPC NBP Pharmaceuticals Co. Ltd. entered an agreement that will grant it exclusive rights to Harbour Biomed Co. Ltd.’s anti-FcRn antibody, batoclimab (HBM-9161), in greater China, including Hong Kong, Macau and Taiwan.

BioWorld BioWorld Asia Deals and M&A Immune Asia-Pacific China

Today's news in brief

BioWorld

BioWorld briefs for Nov. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 27, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Upgrade your daily dose of biopharma and medtech news

CSPC NBP gains China rights to Harbour’s batoclimab for ¥150M up front